Fennec Pharmaceuticals Inc. (FRX.TO)

13.27 +0.30 (+2.31%) At close: 03:52PM EST

Fennec Pharmaceuticals Inc.

68 TW Alexander Drive
PO Box 13628
Research Triangle Park, NC 27709
United States
919 636 4530
https://www.fennecpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 10

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Rostislav Raykov	CEO & Director	468.45k	N/A	1976
Mr. Robert C. Andrade	Chief Financial Officer	339.41k	N/A	1975
Mr. Mark Meier	Sr. VP of Commercial	N/A	N/A	N/A
Mr. Mark Gowland	Controller	N/A	N/A	N/A
Mr. Lei Fang	Pres of Pharstat Inc	N/A	N/A	N/A
Ms. Anne McKay	Regulatory Consultant	N/A	N/A	1954
Mr. Alexander D. Smith M.S.	Consultant	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Corporate Governance

Fennec Pharmaceuticals Inc.’s ISS Governance QualityScore as of December 1, 2022 is 6. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.